Dyne Therapeutics slips after $200 mln stock offering launch

Dyne Therapeutics

30/06/2025 21:24

**  Shares of Dyne Therapeutics DYN.O down 7.8% to $8.78 post-market as co looks to raise equity

** Co focused on neuromuscular diseases commences $200 mln stock offering

** Morgan Stanley, Jefferies, Stifel and Guggenheim are jt bookrunners

** Waltham, Massachusetts-based firm also announces it secured up to $275 mln in debt financing from Hercules Capital

** With ~113.7 mln shares outstanding, DYN has $1.1 bln market cap

** DYN shares on Mon closed down 0.5% at $9.52

** On Jun 17, stock fell 21% to close at $10.86 after co revised timelines for its genetic disorder therapy following meeting with the FDA

** Through Mon, stock has shed ~60% YTD

 (Lance Tupper is a Reuters market analyst. The views expressed are his own)

 ((lance.tupper@tr.com 1-646-279-6380))